LinkedIn · May 2026
Announces EditABLE, an open-source CRISPR experiment-design tool, and says the work supports Nephrogen’s kidney-disease therapeutic pipeline.
Curative gene therapies for kidney diseases
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Stanford-origin biotech spinout developing NeFIND, an AI and high-throughput in vivo screening platform for kidney- and pancreas-targeted gene delivery; the company’s lead focus is curative genetic medicines for PKD and other hard-to-deliver renal/pancreatic diseases.
Primary product
NeFIND AI screening platform for kidney/pancreas-targeted AAV and gene-delivery vehicle discovery
Founded
2022
Headquarters
New York, New York, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Gene therapy / genetic medicine
Offices
1361 Amsterdam Ave, Suite 320, New York, NY 10027
Open Positions
0 jobs at Nephrogen
No open positions
Check back later for new openings